At the close of October, EXMceuticals announced it had obtained a license for cannabis research and development from INFARMED, the Portuguese National Authority of Medicines and Health Products. The granting of the Portuguese license is a key advance as it offers the company the chance to widen its reach in Europe. Thanks to its receipt, EXMceuticals will have the chance to import, research and refine its cannabinoids and cannabis products in Europe.
The Portuguese license enables the company to import raw material from Africa into Portugal and refine it inside an existing R&D facility and pilot refinery.
EXMceuticals is now actively pushing forward with an initial cannabis importation, as well as the fit-out and licensing of the sizable industrial facility that has been leased to the south of Lisbon. Once licensed and constructed, this facility will require a substantial amount of raw and processed cannabis material to be available for refining.
“With its Portuguese license, EXMceuticals is making a leap forward with regards to its activities in the country and the European Union,” EXMceuticals said in a statement.
Last month, EXMceuticals took part in Portugal Medical Cannabis 2019, where studies on the medical benefits of cannabis were discussed by more than 400 cannabis industry executives.
Also on the list of company highlights was a recent interview with Investing News by chairman Jonathan Summers and chief operating officer Tanek Amin, which offered insights about how EXMceuticals has adopted a pharmaceutical-like approach to the cannabis market.
Other recent interviews included an October update on EXMceuticals’ work in Portugal by vice-president Julie Lemiuex at the MjMicro Conference in Beverly Hills as well as a presentation on milestones and financial projections by chairman Jonathan Summers at the German Equity Forum last November.